Silvia Lucano‐Landeros

Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C

Lucia Flores-Contreras, Ana Sandoval-Rodríguez, Mayra G. Mena-Enriquez et al. · BMC Gastroenterology · 2014 · 79 citations · Full text

Controlled Clinical Trial With Pirfenidone in the Treatment of Breast Capsular Contracture

Evelin Rosaira Veras-Castillo, Lázaro Cárdenas-Camarena, Iván Lyra-González et al. · Annals of Plastic Surgery · 2011 · 35 citations

Pirfenidone Accelerates Wound Healing in Chronic Diabetic Foot Ulcers: A Randomized, Double-Blind Controlled Trial

Luz Elena Gasca-Lozano, Silvia Lucano‐Landeros, Héctor Ruiz-Mercado et al. · Journal of Diabetes Research · 2017 · 31 citations · Full text

Hepatocarcinogenesis Prevention by Pirfenidone Is PPARγ Mediated and Involves Modification of Nuclear NF-kB p65/p50 Ratio

Jorge Antonio Silva-Gómez, Marina Galicia‐Moreno, Ana Sandoval-Rodríguez et al. · International Journal of Molecular Sciences · 2021 · 26 citations · Full text

Hepatocarcinogenesis Prevention, Apoptosis, Pathology +19

Adenoviral delivery of dominant‐negative transforming growth factor β type II receptor up‐regulates transcriptional repressor SKI‐like oncogene, decreases matrix metalloproteinase 2 in hepatic stellate cell and prevents liver fibrosis in rats

Ana Laura Márquez-Aguirre, Ana Sandoval-Rodríguez, J. González-Cuevas et al. · The Journal of Gene Medicine · 2009 · 25 citations